Oscar Health CTO granted RSUs, sells some shares

Oscar Health, Inc. President of Technology & CTO Mario Schlosser reported two transactions in Class A common stock.

Rhea-AI Filing Summary

Oscar Health, Inc. President of Technology & CTO Mario Schlosser reported two transactions in Class A common stock. He received 189,141 shares as a grant of restricted stock units at a price of $0.00 per share, which are scheduled to vest quarterly in 12 equal installments beginning on June 1, 2026, subject to his continuous service.

He also sold 24,335 shares at a weighted average price of $13.39 per share under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding tied to earlier equity awards. Following these transactions, he directly owned 514,986 shares, including shares to be issued upon future vesting of restricted stock units.

Insider Trade Summary

Net Seller: 24,335 shares

Net Sell 2 txns

Insider Schlosser Mario

Role President of Technology & CTO

Sold 24,335 shs ($326K)

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	189,141	$0.00	$0.00
Sale	Class A Common Stock	24,335	$13.39	$326K

Holdings After Transaction: Class A Common Stock — 514,986 shares (Direct)

Footnotes (4)

1. F1. The shares represent restricted stock units, which will vest quarterly in 12 equal installments beginning on June 1, 2026, subject to the reporting person's continuous service through each vesting date.
2. F2. Includes shares to be issued in connection with the vesting of one or more restricted stock units.
3. F3. The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on August 8, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of previously granted equity awards.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Oscar Health (OSCR) report for Mario Schlosser?

Oscar Health reported that Mario Schlosser received 189,141 restricted stock units and sold 24,335 Class A common shares. The grant was at $0.00 per share, while the sale occurred at a weighted average price of $13.39 per share under a Rule 10b5-1 plan.

How will Mario Schlosser’s 189,141 Oscar Health (OSCR) RSUs vest?

The 189,141 restricted stock units will vest quarterly in 12 equal installments starting June 1, 2026. Each vesting date requires Mario Schlosser to maintain continuous service at Oscar Health for that portion to become fully earned and settled in shares.

Why did Mario Schlosser sell 24,335 Oscar Health (OSCR) shares?

Mario Schlosser’s sale of 24,335 shares was executed under a Rule 10b5-1 instruction letter to satisfy tax withholding obligations. These obligations arose from the vesting of previously granted equity awards, rather than from discretionary selling of newly awarded stock.

What was the sale price range for Mario Schlosser’s Oscar Health (OSCR) shares?

The reported weighted average sale price was $13.39 per share for 24,335 shares. Individual trades occurred at prices ranging from $13.00 to $13.85, and detailed trade-level information is available upon request from Oscar Health, security holders, or regulators.

How many Oscar Health (OSCR) shares does Mario Schlosser own after these transactions?

After the reported grant and sale, Mario Schlosser directly owned 514,986 Class A common shares. This figure includes shares that will be issued in the future as restricted stock units vest over time, assuming the service-based vesting conditions are met.

What does the Rule 10b5-1 plan mean for Oscar Health (OSCR) insider sales?

A Rule 10b5-1 instruction letter pre-schedules trades based on predefined terms, helping separate them from day-to-day market decisions. In this case, it governed Schlosser’s sale of 24,335 shares to cover tax withholding tied to previously vested equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schlosser Mario

(Last) (First) (Middle)

75 VARICK STREET, 5TH FLOOR

(Street)

NEW YORK NY 10013

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oscar Health, Inc. [ OSCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President of Technology & CTO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/02/2026		A		189,141(1)	A	$0	539,321(2)	D
Class A Common Stock	03/02/2026		S		24,335(3)	D	$13.39(4)	514,986	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares represent restricted stock units, which will vest quarterly in 12 equal installments beginning on June 1, 2026, subject to the reporting person's continuous service through each vesting date.

2. Includes shares to be issued in connection with the vesting of one or more restricted stock units.

3. The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on August 8, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of previously granted equity awards.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Remarks:

	/s/ Melissa Curtin, Attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.